Almirall

Almirall, a pharmaceutical preparation manufacturing company headquartered in Spain, has demonstrated a commitment to reducing its environmental impact through various climate initiatives and emissions reporting.

Carbon Emissions Data:

In 2024, Almirall reported a total of approximately 147.6 million kg CO2e. This figure is comprised of:

• Scope 1 emissions: Approximately 5.7 million kg CO2e, primarily from stationary combustion and mobile combustion.
• Scope 2 emissions: Approximately 3.8 million kg CO2e (location-based).
• Scope 3 emissions: Approximately 141.9 million kg CO2e, with purchased goods and services being the largest contributor, followed by business travel.

In 2023, the company's total emissions were approximately 162.8 million kg CO2e, with Scope 3 emissions accounting for around 156.7 million kg CO2e.

Climate Commitments and Reduction Targets:

Almirall has set ambitious targets aligned with climate science. The company is committed to:

• Net-Zero Emissions by 2050: Almirall aims to achieve net-zero greenhouse gas emissions across its entire value chain by 2050, using 2019 as a base year.
• Near-Term Reductions (by 2030):
  • An absolute reduction of 50% in Scope 1 and Scope 2 greenhouse gas emissions compared to the 2019 baseline.
  • An absolute reduction of 28% in Scope 3 greenhouse gas emissions compared to the 2019 baseline.
  • Continued annual sourcing of 100% renewable electricity through 2030.

These commitments are further reinforced by Science Based Targets initiative (SBTi) validation. Almirall's Scope 1 and 2 targets are considered consistent with the 1.5°C warming scenario. Additionally, the company has a long-term target to reduce absolute Scope 1, 2, and 3 greenhouse gas emissions by 90% by 2050 from a 2019 base year.